These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy. Kalveram B, Lihoradova O, Indran SV, Ikegami T. J Vis Exp; 2011 Nov 01; (57):e3400. PubMed ID: 22083261 [Abstract] [Full Text] [Related]
26. Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus. Lihoradova OA, Indran SV, Kalveram B, Lokugamage N, Head JA, Gong B, Tigabu B, Juelich TL, Freiberg AN, Ikegami T. PLoS Negl Trop Dis; 2013 Nov 01; 7(4):e2181. PubMed ID: 23638202 [Abstract] [Full Text] [Related]
27. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Morrill JC, Mebus CA, Peters CJ. Am J Vet Res; 1997 Oct 01; 58(10):1110-4. PubMed ID: 9328663 [Abstract] [Full Text] [Related]
33. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Morrill JC, Laughlin RC, Lokugamage N, Wu J, Pugh R, Kanani P, Adams LG, Makino S, Peters CJ. Vaccine; 2013 Oct 09; 31(43):4988-94. PubMed ID: 23994375 [Abstract] [Full Text] [Related]
34. Comparative efficacy of two next-generation Rift Valley fever vaccines. Kortekaas J, Oreshkova N, van Keulen L, Kant J, Bosch BJ, Bouloy M, Moulin V, Goovaerts D, Moormann RJ. Vaccine; 2014 Sep 03; 32(39):4901-8. PubMed ID: 25050973 [Abstract] [Full Text] [Related]
35. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Näslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, Weber F, Bucht G. Virology; 2009 Mar 15; 385(2):409-15. PubMed ID: 19157482 [Abstract] [Full Text] [Related]
36. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Faburay B, Lebedev M, McVey DS, Wilson W, Morozov I, Young A, Richt JA. Vector Borne Zoonotic Dis; 2014 Oct 15; 14(10):746-56. PubMed ID: 25325319 [Abstract] [Full Text] [Related]
37. The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation. Borrego B, Alonso C, Moreno S, de la Losa N, Sánchez-Cordón PJ, Brun A. PLoS Negl Trop Dis; 2024 Aug 15; 18(8):e0012011. PubMed ID: 39159263 [Abstract] [Full Text] [Related]
38. Rift Valley fever vaccines: current and future needs. Dungu B, Lubisi BA, Ikegami T. Curr Opin Virol; 2018 Apr 15; 29():8-15. PubMed ID: 29514112 [Abstract] [Full Text] [Related]
39. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Morrill JC, Laughlin RC, Lokugamage N, Pugh R, Sbrana E, Weise WJ, Adams LG, Makino S, Peters CJ. Vaccine; 2013 Jan 07; 31(3):559-65. PubMed ID: 23153443 [Abstract] [Full Text] [Related]
40. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. Lihoradova O, Kalveram B, Indran SV, Lokugamage N, Juelich TL, Hill TE, Tseng CT, Gong B, Fukushi S, Morikawa S, Freiberg AN, Ikegami T. J Virol; 2012 Jul 07; 86(14):7650-61. PubMed ID: 22573861 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]